Table 1 Patient-reported demographics and clinical characteristics
Patients N = 94 | |
|---|---|
Gender, n (%) | |
Female | 78 (83) |
Male | 14 (15) |
Non-binary | 2 (2) |
Mean (median) age, years | 49.2 (49) |
Race, n (%) | |
White or Caucasian | 84 (89) |
Black or African American | 8 (9) |
Asian | 1 (1) |
Other | 1 (1) |
Ethnicity, n (%) | |
Non-Hispanic or -Latino | 89 (95) |
Hispanic or Latino | 5 (5) |
Mean (median) years since migraine diagnosis | 15.4 (12) |
Primary insurance type | |
Commercial/employer | 47 (50) |
Medicare | 35 (37) |
Medicaid | 6 (6) |
Other | 6 (6) |
Comorbidities, n (%) | |
Psychiatric conditions | 61 (65) |
Anxiety | 47 (50) |
Depression | 45 (48) |
Bipolar disorder | 3 (3) |
Other | 4 (4) |
Allergies | 53 (56) |
Cardiovascular disease | 38 (40) |
Hypertension or high blood pressure | 35 (37) |
Heart attack | 2 (2) |
Heart disease | 1 (1) |
Inflammatory conditions | 37 (39) |
Fibromyalgia | 16 (17) |
Rheumatoid arthritis | 11 (12) |
Other pain/inflammation | 26 (28) |
Digestive system conditions | 36 (38) |
Sleep apnea | 25 (27) |
Asthma | 15 (16) |
Number of eptinezumab infusions received, n (%) | |
1a | 1 (1) |
2 | 12 (13) |
3 | 15 (16) |
4 | 17 (18) |
5 or more | 48 (52) |
Missing | 1 (1) |
Current eptinezumab dose received, n (%) | |
100 mg | 22 (23) |
300 mg | 54 (57) |
Other | 2 (2) |
Cannot recall | 13 (14) |
Missing | 3 (3) |
Previously received another preventive therapy, n (%) | 94 (100) |
Previous therapy types, n (%)b | |
Prior subcutaneous anti-CGRP mAb | 84 (89) |
OnabotulinumtoxinA | 77 (82) |
Oral preventive | 70 (74) |
Gepantc | 69 (73) |